Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GLP111892
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 08 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned initiation date changed from 1 Oct 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.